



CONFERENCE AGENDA

Tuesday, March 29, 2022	
10:00 am – 11:30 am	Pre-Conference Educational Session <i>Moderator: Megan Crumpler, PhD, Orange County Health Care Agency</i>
10:00 am – 10:15 am	ES1. Impacts of the COVID-19 Pandemic on Advancing HIV, STI and Viral Hepatitis Testing <i>Megan Crumpler, PhD, Conference Co-Chair, Orange County Health Care Agency</i>
10:15 am – 10:30 am	ES2. Overview of HIV Testing Practices and Technology <i>Michele S. Owen, PhD, Centers for Disease Control and Prevention</i>
10:30 am – 10:45 am	ES3. STI Testing Technology <i>Barbara Van der Pol, PhD, American Sexually Transmitted Diseases Association</i>
10:45 am – 11:00 am	ES4. Hepatitis C Virus Test Technology <i>Saleem Kamili, PhD, Centers for Disease Control and Prevention</i>
11:00 am – 11:15 am	ES5. Debrief of the HCV Diagnostics Conference <i>Carolyn Wester, MD, Centers for Disease Control and Prevention</i> <i>Anne Gaynor, PhD, Association of Public Health Laboratories</i>
11:15 am – 11:30 am	Moderated Q & A
11:30 am – 12:00 pm	Break
12:00 pm – 1:00 pm	Opening Session: Testing as a Gateway to Prevention and Care Welcome <i>Rochelle Walensky, MD, Director of the Centers for Disease Control and Prevention</i> Invited Speakers Moderator: Jonathan Mermin, MD, MPH, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC Panelists: Demetre Daskalakis, MD, Director of the Division of HIV Prevention at the National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

	<p>Leandro Mena, MD, Director of the Division of STD Prevention at the National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC</p> <p>Carolyn Wester, MD, Director of the Division of Viral Hepatitis at the National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC</p>
1:00 pm – 1:30 pm	Lunch Break
1:30 pm – 2:00 pm	<p>Live Chat Poster Session A</p> <p>Chat discussion with poster presenters is available on the conference platform throughout the conference.</p> <p>Attendees are especially encouraged to engage with these poster presenters during Poster Session A:</p>
	<p>PA1. Evaluation of the Abbott Alinity m STI assay for diagnosis of the primary causes of sexually transmitted infections in the United States</p> <p>James E. Kirby, MD D(ABMM), Beth Israel Deaconess Medical Center, Harvard Medical School</p>
	<p>PA2. Performance of Self-collected Penile-meatal Swabs Compared to Urine for Detection of STIs in a Low Resource Setting with High Prevalence of STIs</p> <p>Johan H. Melendez, PhD, Johns Hopkins University School of Medicine</p>
	<p>PA3. Evaluation of the Alinity m STI Assay at a Veterans Administration Hospital</p> <p>Robert J. Rolfe, MD, Duke University Health System, Clinical Microbiology Laboratory</p>
	<p>PA4. Real-World HIV Diagnostic Testing in the United States: Assessing the 2nd Step of the Algorithm</p> <p>Sara Blosser, PhD, D(ABMM), Roche Diagnostics Corporation</p>
	<p>PA5. Implementation of HCV RNA testing at a Local Public Health Laboratory</p> <p>Mariam Zhouwandai, MPH, Orange County Public Health Laboratory, CA</p>
2:00 pm – 3:30 pm	<p>Session 1: Nucleic Acid Tests</p> <p>Moderator: Jeffery A. Johnson, PhD, Centers for Disease Control and Prevention</p>
2:00 PM – 2:15 PM	<p>1A. A Shared Service Model for HIV Nucleic Acid Testing and the Impact of COVID-19</p> <p>Lauren Johnson, MPH, Association of Public Health Laboratories</p>
2:15 PM – 2:30 PM	<p>1B. Multisite Evaluation of an HIV-1 panel on the Alinity m HIV-1 assay and its relevance to critical clinical decision points</p> <p>Whitnie Crown, MS, M(ASCP)MB, Abbott Laboratories</p>
2:30 PM – 2:45 PM	<p>1C. HIV/HCV Screening, Testing, and Diagnostic Reliability during the Acute Encounter with the Cepheid GeneXpert</p> <p>Jason Wilson, MD, MA, FACEP, University of South Florida, Tampa General Hospital</p>

2:45 PM – 3:00 PM	1D. Evaluation of the Aptima HCV Quant Dx Assay for qualitative and quantitative RNA detection in Dried Blood Spots <i>Renee Hallack, BS, New York State Department of Health, Wadsworth Center</i>
3:00 PM – 3:15 PM	1E. Validation of new STI panel for Abbott Alinity m <i>Karen C. Rexroth, M(ASCP), Veterans Affairs Medical Center</i>
3:15 PM – 3:30 PM	1F. The Clinical and Cost Implications of Using HIV RNA Instead of Antibody Testing to Confirm Reactive HIV Screening Tests in the United States <i>Daniel Gromer, MD, Emory University School of Medicine</i>
3:30 pm – 3:45 pm	Live Moderated Q&A
3:45 pm – 4:00 pm	Break
4:00 pm – 5:00 pm	Discussion Panel <i>Using a molecular test as the second test in the HIV diagnostic algorithm</i> Moderator: <i>S. Michele Owen, PhD, Centers for Disease Control and Prevention</i> Discussants: <i>Bernard Branson, MD, Scientific Affairs Inc.</i> <i>Monica Parker, PhD, Wadsworth Center, New York State Department of Health</i> <i>S. Berry Bennett, MPH, Florida Bureau of Public Health Laboratories</i> <i>Joseph Yao, MD, Viral Hepatitis/HIV Testing Laboratory, Mayo Clinic</i> <i>Jeffery A. Johnson, PhD, Centers for Disease Control and Prevention</i>
Wednesday, March 30, 2022	
10:00 am – 11:00 am	Discussion Panel <i>The utility of multiplex versus singleplex or lower plex testing in STI diagnostics</i> Moderator: <i>Barbara Van Der Pol, PhD, American Sexually Transmitted Diseases Association</i> Discussants: <i>James Kirby, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School</i> <i>Katherine Hsu, MD, Massachusetts Department of Public Health</i> <i>Kevin Ard, MD, MPH, Massachusetts General Hospital</i> <i>Eric Hardy,</i> <i>Christina Muzny, MD, MSPH, University of Alabama at Birmingham</i>
11:00 am — 11:15 am	Morning Break
11:15 am – 12:15 pm	Session 2: Recently Marketed Tests Moderator: <i>Ellen Kersh, PhD, Centers for Disease Control and Prevention</i>

11:15 am – 11:30 am	2A. Evaluation of the DPP HIV-Syphilis test performance characteristics at the point-of-care clinical setting (FDOH-Miami-Dade STD clinical lab). <i>Olga V. Ponomareva, Florida Department of Health in Miami-Dade County</i>
11:30 am- 11:45 am	2B. Performance of the Avioq VioOne HIV Profile Supplemental Assay for Confirmation and Differentiation of HIV-1 and HIV-2 Antibodies at a State Public Health Laboratory. <i>S. Berry Bennett, MPH, Florida Bureau of Public Health Laboratories</i>
11:45 am – 12:00 pm	2C. Visby Medical Sexual Health Click test: A patient-centric approach to diagnosing sexually transmitted infections <i>Gary Schoolnik, MD, CMO Visby Medical</i>
12:00 pm - 12:15 pm	Live Moderated Q&A
12:15 pm – 1:15 pm	Lunch Break/Satellite Demo Product Hologic
1:15 pm – 1:45 pm	Live Chat Poster Session B <i>Chat discussion with poster presenters is available on the conference platform throughout the conference.</i> <i>Attendees are especially encouraged to engage with these poster presenters during Poster Session B:</i>
	PB1. Hepatitis C Testing during a Global Pandemic: San Francisco's Lessons Learned <i>Shelley N. Facente, PhD, MPH, University of California, Berkeley Facente Consulting</i>
	PB2. Factors Associated with Accepting HIV tests in the United States: A Systematic Review <i>Titilola Labisi, MHA, MPH, University of Nebraska Medical Center</i>
	PB3. Patient Flow Assessed in Preparation for Point-of-care HIV Nucleic Acid Testing (POC NAT) Implementation at a Large HIV Clinic in Seattle, Washington <i>Lisa A Niemann, MSW/MPH, University of Washington</i>
	PB4. Analyzing Trends in HSV Western Blot Results at a Reference Laboratory <i>Abir Hussein, MD, MPH, University of Washington</i>
	PB5. False Positive Results on HSV 2 Confirmatory Test Used at Major US Laboratory Compared to Gold Standard Herpes Western Blot <i>Terri Warren, BA, BSN, MEd, MSN, ANP, Westover Research Group</i>
1:45 pm – 3:15 pm	Session 3: Optimizing Testing Opportunities Moderator: Jenny R. MacFarlane, BA, Texas Department of State Health Services (retired)

1:45 pm - 2:00 pm	3A. Testing 1-2-3: A Novel Approach to STI/HIV testing in Rhode Island <i>Siena Napoleon, MPH, Brown University Warren Alpert School of Medicine</i>
2:00 pm – 2:15 pm	3B. CDC’s Direct-to-consumer Distribution of 100,000 HIV self-tests <i>Pollyanna R. Chavez, PhD, Centers for Disease Control and Prevention</i>
2:15 pm – 2:30 pm	3C. Infectious Disease Testing at a Syringe Services Program (SSP) <i>Heather Henderson, MA, Morsani College of Medicine, University of South Florida, Tampa General Hospital</i>
2:30 pm – 2:45 pm	3D. Promoting HIV and Hepatitis C Virus Testing and Linkage to Harm Reduction Resources Through Navigation Programs <i>Shamia Roberts, BSN, RN, Tennessee Department of Health</i>
2:45 pm – 3:00 pm	3E. Optimizing Hepatitis C Virus Screening using Automation in an Urban Emergency Department <i>Melisa Hart, MPH, Jersey City Medical Center, Center for Comprehensive Care</i>
3:00 pm - 3:15 pm	Moderated Q&A
3:15 pm – 3:30 pm	Break
3:30 pm – 4:30 pm	Discussion Panel: <i>The Reddit Community asks the experts about STIs. Here’s what we discovered...</i> Moderator: <i>Megan Crumpler, PhD, Orange County Health Care Agency, CA</i> Discussants: <i>Barbara Van Der Pol, PhD, American Sexually Transmitted Diseases Association University of Alabama at Birmingham</i> <i>Srishti Baid, MS, University of Kansas</i> <i>Miguel Quinones-Mateu, PhD, University of Otago</i>
Thursday, March 31, 2022	
10:00 am — 11:00 am	Session 4: Testing Challenges Moderator: <i>TBD</i>
10:00 am – 10:15 am	4A. Biotin Interference in Point of Care HIV Immunoassay <i>Mohan Kumar Haleyur Giri Setty, PhD, US Food and Drug Administration</i>
10:15 am – 10:30 am	4B. Equivocal HIV Screening Results in the Emergency Department. False Positive or Acute Seroconversion? <i>Jason Wilson, MD, MA, FACEP, Morsani College of Medicine, University of South Florida Tampa General Hospital</i>

10:30am – 10:45 am	4C. Seroconversion, seroreversion, and serowaffling among participants in Project DETECT <i>Joanne Stekler, MD, University of Washington</i>
10:45am – 11:00 am	4D. Longitudinal Specificity of the BioPlex 2200 HIV Ag-Ab Combination Assay in Routine Screening in a US Public Health Laboratory <i>Alfredo Villareal, BS, MBA, Bio-Rad Laboratories</i>
11:00 am – 11:15 am	4E. Do COVID antibodies cross-react with the BioPlex 2200 HIV Ag-Ab differentiating combination screening assay? <i>Payu A. Raval, MD, Northshore University Healthsystem</i>
11:15 am – 11:30 am	Moderated Q&A
11:30 am – 11:45 am	Break
11:45 am – 12:45 pm	Discussion Panel Opportunities and challenges with using HIV recency testing and other metrics to monitor progress towards Ending the HIV Epidemic <i>Moderator: Kevin Delaney, PhD, Centers for Disease Control and Prevention</i> <i>Discussants:</i> <i>Shelley Facente, PhD, MPH, University of California, Berkeley Facente Consulting TBD</i>
12:45 pm – 1:15 pm	Lunch break
1:15 pm – 1:45 pm	Live Chat Poster Session C <i>Chat discussion with poster presenters is available on the conference platform throughout the conference.</i> <i>Attendees are especially encouraged to engage with these poster presenters during Poster Session C:</i>
	PC1. A comparison of clinical characteristics of neurosyphilis between HIV infected and non-HIV patients at Maharat Nakhon Ratchasima Hospital <i>Chalothorn Wannaphut, MD, Siriraj Piyamaharajkarun Hospital Mahidol University</i>
	PC2. Challenges of PrEP Regimen Adherence and Monitoring of Kidney Function on Self-collect DBS <i>Kavinda DeSilva, Molecular Testing Labs</i>
	PC3. Emergence of Syphilis Infection beyond HIV Infection as a more Relevant Indicator for Hepatitis C Virus Infection Susceptibility <i>Cynthia Turner, PhD, MS, SV(ASCP), Houston Health Department Texas Southern University</i>

	PC4. Self-collect diagnostic options facilitate PrEP engagement and persistence <i>Christopher S. Hall, MD, MS, Molecular Testing Labs</i>
1:45 pm – 3:00 pm	Session 5: Emerging Technology Moderator: <i>Kelly Curtis, PhD, Centers for Disease Control and Prevention</i>
1:45 pm – 2:00 pm	5A. Development of a serologic assay for differentiating acute from chronic HCV infection Matthew Pauly, PhD, Centers for Disease Control and Prevention
2:00 pm – 2:15 pm	5B. A laboratory-developed quantitative hepatitis B surface antigen (qHBsAg) test detects 8 major HBV genotypes and sG145R mutants Mary Lape Nixon, BA, MS, Quest Diagnostics Infectious Diseases, Inc.
2:15 pm – 2:30 pm	5C. Time to leave Fiebig staging in the dust? Estimated Dates of Detectable Infection (EDDIs) as a new and improved method for HIV infection dating Shelley Facente, PhD, MPH, University of California, Berkeley Facente Consulting
2:30 pm – 2:45 pm	5D. Use of the Geenius Index to indicate recent HIV infection in Project DETECT Lauren Violette, MPH, University of Washington
2:45 pm – 3:00 pm	Live Moderated Q&A
3:00 pm – 3:15 pm	Break
3:15 pm – 4:15 pm	Discussion Panel <i>Detecting and confirming acute or incident HIV infection in persons taking antiretrovirals for PrEP</i> Moderator: <i>Dawn Smith, MD, Centers for Disease Control and Prevention</i> Discussants: <i>Mark Marzinke, PhD, Johns Hopkins University School of Medicine</i> <i>Adam Visconti, MD, MPH, MedStar Georgetown University Hospital</i> <i>Raphael Landovitz, MD, UCLA Health Care Center</i> <i>Susan Eshleman, MD, PhD, Johns Hopkins University School of Medicine</i>
Friday, April 1, 2022	
10:00 am – 11:00 am	Feedback Session: Regulatory Issues Related to Self-collection and Remote Testing (led by FDA and CDC) Panelists: <i>Julia Lathrop, PhD, US Food and Drug Administration</i> <i>Himani Bisht, PhD, US Food and Drug Administration</i> <i>S. Michele Owen, PhD, Centers for Disease Control and Prevention</i>

	Ellen Kersh, PhD, Centers for Disease Control and Prevention
11:00 am – 11:15 am	Break
11:15 am – 12:45 pm	Session 6: Mail-in Testing Moderator: Liisa Randall, PhD, Massachusetts Department of Public Health
11:15 am – 11:30 am	6A. Addition of Extragenital STI testing in “I Want The Kit” Program Users Tong Yu, ScM, Johns Hopkins University School of Medicine
11:30 am – 11:45 am	6B. I Want The Kit (IWTK): Improving an online platform for STI specimen at-home self-collection and laboratory testing Gretchen Armington, MA, Johns Hopkins University School of Medicine
11:45 am – 12:00 pm	6C. Preparing for a Home-Based Self-Sampling STI/HIV Testing Pilot Program Ashton Morris, MPH, Michigan Department of Health and Human Services
12:00 pm – 12:15 pm	6D. GetCheckedDC: A Home-Based STI Testing Pilot Program Kenya Troutman, MPH, DC Health
12:15 pm – 12:30 pm	6E. Implementing a novel home HIV/STI testing program Jennifer Hecht, MPH, Building Healthy Online Communities Springboard HealthLab
12:30 pm – 12:45 pm	Moderated Q&A
12:45 pm - 1:15 pm	Lunch Break
1:15 pm – 1:45 pm	Live Chat Poster Session D <i>Chat discussion with poster presenters is available on the conference platform throughout the conference.</i> <i>Attendees are especially encouraged to engage with these poster presenters during Poster Session D:</i>
	PD1. Automated Sexual History and Self-Collection of Chlamydia and Gonorrhea Specimens Improves Diagnoses Kelly S. Chapman, PhD, MPH, MA, Florida Department of Health
	PD2. STI sampling at home: High negative predictive values of self-collection STI screening and the feasibility of such tests with follow-up telemedicine consultation and treatment Daniel Kreitzberg, MS, Everly Health, Inc
	PD3. A review of the scope of direct-to-consumer sexually transmitted infection testing services offered on the internet Casey N. Pinto, PhD, MPH, CRNP, Pennsylvania State University
	PD4. Bacterial Sexually Transmitted Infection Testing and Treating Barriers John A. Nelson, PhD, APRN, Rutgers University

1:45 pm – 2 pm	Break
2:00 pm – 4:00 pm	Session 7: Self-collected Micro-sampling Moderator: Joanne Mei, PhD, Centers for Disease Control and Prevention
2:00 pm – 2:15 pm	7A. Actionable multi-targeted STI testing using self-collect DBS for high-risk populations Zoe Goedecke, Molecular Testing Labs
2:15 pm – 2:30 pm	7B. Validation and prospective evaluation of mailed dried blood spot (DBS) for dual detection of HIV and syphilis using the DPP® HIV-Syphilis test Johan H. Melendez, PhD, Johns Hopkins University School of Medicine
2:30 pm – 2:45 pm	7C. Clinical Utility of Hepatitis C Viral Load Detected via Dried Blood Spot Card At-Home Collection Mariko Nakano, PhD, Molecular Testing Labs
2:45 pm – 3:00 pm	7D. The implementation of self-collected Microtainer™ specimens in a large research project—iSTAMP Amanda J. Smith, MPH, Centers for Disease Control and Prevention
3:00 pm – 3:15 pm	7E. Self-collected Microtainer™ specimens for HIV viral load testing: a step towards HIV telemedicine Jeffrey A. Johnson, PhD, Centers for Disease Control and Prevention
3:15 pm – 3:30 pm	7F. Evaluation of self-collected Microtainer™ specimens for measuring antiretroviral drugs Richard Haaland, PhD, Centers for Disease Control and Prevention
3:30 pm – 4:00 pm	Moderated Discussion on Self-collected Micro-sampling
4:00 pm – 4:15 pm	Break
4:15 pm – 4:45 pm	Closing Statements S. Michele Owen, PhD, Conference Co-Chair, Centers for Disease Control and Prevention